Dr. Richardson on the Use of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
April 5th 2019
Kristin J. Richardson, MD, hematology/oncology fellow at Rush University Medical Center, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.